7.95MMarket Cap-85P/E (TTM)
0.8879High0.8700Low63.64KVolume0.8752Open0.8894Pre Close55.70KTurnover1.09%Turnover RatioLossP/E (Static)9.07MShares9.740052wk High1.33P/B5.14MFloat Cap0.670052wk Low--Dividend TTM5.86MShs Float587200.0000Historical High--Div YieldTTM2.01%Amplitude0.6700Historical Low0.8750Avg Price1Lot Size
Biodexa Pharmaceuticals Stock Forum
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) recently announced promising results from a Phase 1 study of MTX110, an investigational drug for the treatment of Diffuse Midline Glioma (DMG), also known as Diffuse Intrinsic Pontine Glioma (DIPG). These results were presented at the 21st Internati...
Benzinga· 3 mins ago
Benzinga· 2 mins ago
Biodexa Pharmaceuticals Announces Phase 2 Trial Results Of ERapa In Familial Adenomatous Polyposis; 75% Non-Progression Rate At 12 Months, 17% Median Decrease In Polyp Burden; Cohort 2...
Biodexa Pharmaceuticals (NASDAQ:BDRX) has recently announced promising phase 2 results for its newly in-licensed drug, eRapa, aimed at treating familial adenomatous polyposis (FAP). FAP is a primarily genetic disease of the lower gastrointestinal (GI) tract for which there is currently no remedy except surgical removal of the colon and/or rectum....
No comment yet